Draximage MAA Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Draximage MAA market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historical period can be attributed to the increasing demand for accurate disease diagnoses, the rising prevalence of cancer, the growing adoption of PET scanning technology, improved access to healthcare, global infrastructure development, and increased government investments in healthcare.

The growth projected for the forecast period can be attributed to the growing demand for preventive healthcare, the rising prevalence of chronic diseases, an increased focus on personalized medicine, higher healthcare spending, and greater awareness of the importance of non-invasive diagnostic procedures. Key trends in the forecast period include advancements in radiopharmaceuticals for more precise disease targeting, the adoption of multimodal imaging technologies, innovations in imaging agents to detect a broader range of diseases, the integration of cloud-based platforms for real-time data sharing and analysis, and the development of automated diagnostic systems.

The rising incidence of lung cancer is expected to drive the growth of the draximage MAA market in the future. Lung cancer, a disease that begins in the lungs and is characterized by abnormal and uncontrolled cell growth, can spread to other parts of the body. The increasing incidence of lung cancer is attributed to several factors, including the persistent prevalence of smoking, exposure to environmental pollutants such as air pollution and secondhand smoke, occupational hazards such as asbestos and radon, and an aging population. Draximage MAA aids in diagnosing, staging, and monitoring treatment responses for lung cancer through positron emission tomography (PET) imaging, improving the accuracy of lung cancer assessments and enhancing patient management strategies. For example, in January 2024, the American Cancer Society reported approximately 234,580 new cases of lung cancer in the U.S., including 116,310 men and 118,270 women, with 125,070 deaths, including 65,790 men and 59,280 women. This indicates a slightly higher incidence in women but a higher mortality rate in men. As a result, the increasing incidence of lung cancer is driving the growth of the draximage MAA market.

The growing demand for medical imaging is expected to propel the expansion of the draximage MAA market. Medical imaging uses techniques to create visual representations of the inside of the body for diagnostic and therapeutic purposes. Several factors contribute to the rising demand for medical imaging, including an aging population, a higher prevalence of chronic diseases, improved healthcare infrastructure, and a shift towards minimally invasive procedures. Draximage MAA supports medical imaging by providing a radiopharmaceutical used in scintigraphy to visualize and assess pulmonary function, improving imaging accuracy for detecting conditions such as pulmonary embolisms and evaluating lung health. This ultimately leads to more accurate diagnoses and better treatment planning. For instance, in May 2023, the National Health Service in the UK reported an increase in the number of magnetic resonance imaging (MRI) activities referred by general practitioners, from 8,695 in January 2022 to 8,745 in January 2023. Additionally, the NHS reported 43.4 million imaging tests performed in England between February 2022 and January 2023. Consequently, the rising demand for medical imaging is driving the growth of the draximage MAA market.

The growth of the geriatric population is key factor contributing to the expansion of the draximage MAA market. The geriatric population, typically individuals aged 65 and older, is growing due to factors such as an aging global population, improvements in healthcare, and advancements in medical treatments that have extended life expectancy. Draximage MAA aids the geriatric population by providing a radiopharmaceutical used in medical imaging to accurately assess pulmonary function, detect conditions such as pulmonary embolisms, and monitor respiratory health. This is particularly important for older adults, who often have multiple comorbidities and require precise diagnoses for effective treatment planning. For instance, in January 2024, the Population Reference Bureau reported that the U.S. population aged 65 and older is expected to increase from 58 million in 2022 to 82 million by 2050, marking a 47% rise. The share of this age group in the overall population is projected to grow from 17% to 23% during the same period. Therefore, the growing geriatric population is driving the growth of the draximage MAA market.

The key companies operating in the draximage MAA market is Jubilant Draximage Inc.

North America was the largest region in the draximage MAA market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in draximage MAA report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the Draximage MAA market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Draximage MAA is a radiopharmaceutical used in nuclear medicine for lung imaging. It consists of macro-aggregated albumin (MAA) labeled with technetium-99m, which facilitates ventilation/perfusion (V/Q) lung scans to assess pulmonary function. The radiolabeled particles are injected into the body and monitored using a gamma camera to evaluate lung function and detect any abnormalities.

The primary indications for draximage MAA include lymphatic mapping and sentinel lymph node biopsy. In lymphatic mapping, Draximage MAA helps identify lymph nodes that drain specific areas of the body, assisting in cancer diagnosis and guiding surgical planning by detecting potential cancer spread. It is distributed through various channels, such as hospital pharmacies, radiopharmacy services, and outpatient surgical centers. End users include hospitals, clinics, ambulatory care centers, and home care settings.

The draximage MAA market research report is one of a series of new reports that provides draximage MAA market statistics, including the draximage MAA industry global market size, regional shares, competitors with the draximage MAA market share, detailed draximage MAA market segments, market trends, and opportunities, and any further data you may need to thrive in the draximage MAA industry. This draximage MAA market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The draximage MAA market consists of sales of draximage MAA with human serum albumin and draximage MAA radiolabeled. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.